Everest Medicines is an late-clinical biopharmaceutical company dedicated to licensing, developing and commercializing innovative therapies globally, with the goal of addressing critical unmet healthcare needs in Greater China and other emerging Asia Pacific markets. Our world-class clinical and regulatory teams, insight-driven business development engines, and integrated commercial platforms enable us to accelerate the delivery of innovative new medicines to patients. Since our establishment in 2017, we have brought together eight promising clinical-stage drug candidates for oncology, immunology, heart and kidney diseases, and infectious diseases. We target these four treatment areas based on the severity of unmet medical needs, the size of the high-risk patient population, and the emergence of innovative products around the world.
No Data
No Data